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Abstract 
 
Estrogens play a crucial role in the development and function of female reproductive tissues. 
They have positive effects on the maintenance of bone mineral density, on the liver, and on the 
cardiovascular and central nervous systems. 
Selective Estrogen Receptor Modulators (SERMs) are particularly attractive as therapeutic 
agents because they are able to block estrogen action at those sites where stimulation would be 
undesirable, such as the breast and uterus, but at the same time stimulate estrogen actions in 
other tissues where they are desired, such as the bone and liver. 
Most synthetic estrogen receptor ligands possess a phenolic ring, mimicking the phenolic "A-
ring" of the natural ligand estradiol. 
In an attempt to increase the structural diversity of estrogen receptor (ER) ligands, we 
designed and synthesized molecules containing unprecedented replacements of the prototypical 
phenolic "A-ring" of estrogens with an oxime and a hydroxy- (salicylaldoximes) or amino-
moieties (anthranylaldoximes), forming intramolecularly H-bonded pseudocycles. These new 
classes of compounds showed interesting ER binding properties on both receptor subtypes (ERα 
and ERβ). These results proved that the six-membered ring formed by an intramolecular 
hydrogen bond, and containing an exocyclic oxime OH, is an effective stereoelectronic 
replacement of the phenolic ring of typical ER ligands. 
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Introduction 
 
Many important physiological processes may be regulated by an appropriate modulation of the 
estrogen receptors (ER). For example, an ER agonist action has positive effects in estrogen 
deficiencies (hormone replacement therapy), in the maintenance of bone mineral density 
(osteoporosis), in lowering blood lipid levels (atherosclerosis and other cardiovascular diseases), 
and in the central nervous system functions.1-3 On the other hand, an estrogen agonist action on 
uterus and breast may increase the risk of cancer insurgence in those tissues.4,5 For these reasons, 
molecules able to antagonize the tumor-promoting effect of endogenous estrogens and, at the 
same time, to promote estrogen-like effects in tissues where they are desired, are named 
“Selective Estrogen Receptor Modulators” or “SERMs” (Figure 1).6-9
 
 
 
Figure 1 
 
Nowadays, two subtypes of the ER have been identified, ERα and ERβ,10 and they act as 
ligand-inducible nuclear transcription factors (Figure 2).11 Their action is always influenced by 
the presence of coregulatory proteins (coactivators, corepressors, etc.) within the cells of 
different tissues, which eventually determine the final physiological effects.12
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Figure 2 
 
 
Results and Discussion 
 
In spite of a remarkable variety of molecular structures found in the many classes of non-
steroidal ER ligands known so far, a striking chemical feature common to nearly all synthetic ER 
ligands possessing a good binding affinity is the presence of a phenolic ring (A, pharmacophore 
model, Figure 3) that seems to mimic the steroid "A-ring" present in natural estrogens.13 This 
phenolic group is thought to be responsible for much of the binding energy between ligand and 
receptor, because of its participation in a hydrogen-bond network which includes two specific 
residues of the ER ligand binding domain, Glu353(305) and Arg394(346) of ERα(ERβ).14,15
In an investigation of new molecular entities that might bind to the ER with improved SERM 
properties, and thereby increase the structural diversity of estrogen ligands, we have developed 
3,4-diaryl-substituted salicylaldoxime and anthranylaldoxime ligands (Figure 3).16-19 These 
classes of compounds possess an unprecedented bioisosteric replacement of the phenolic A 
group with hydroxy-substituted 6-membered pseudo-rings (A'), formed by an intramolecular 
hydrogen bond. This ring (A') presents several features that indicate its similarity with the 
phenolic A-ring: (i) both rings have approximately same size and same planar π-conjugated (at 
least partially, in the case of the salicylaldoximes) hexagonal geometry; (ii) the OH of the oxime 
group is attached to an sp2 hybridized atom (nitrogen) that is intramolecularly hydrogen-bonded 
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to the ortho phenol, and has an estimated pKa value around 10, within the pKa range of typical 
phenolic OH groups; and (iii) the position of the oxime OH group corresponds to the position 3 
of the phenolic A ring, i.e., the position actually occupied by an OH in classical ER ligands 
(Figure 3). 
 
 
 
Figure 3 
 
The binding affinities of these new compounds were determined in radiometric competitive 
binding assays with purified full-length human ERα and ERβ. The data reported in Figure 4 are 
expressed as the relative binding affinity (RBA) values relative to estradiol, which is set at 
100%.20,21 The affinity of estradiol for the two receptors is high: Kd(ERα) 0.2 nM; Kd (ERβ) 0.5 
nM. 
The diphenylsubstituted salicylaldoxime already proved to have interesting binding 
properties for both estrogen receptor subtypes (RBA = 1.1% with ERα and 1.7% with ERβ), thus 
confirming the good hypothesized mimicry of the pseudocycle A’ for the phenol group of typical 
ER ligands. We then replaced the oxygen atom of the pseudocycle with an aniline-type 
unsubstituted nitrogen, and the resulting N-H-anthranylaldoxime showed an improved binding 
affinity on both ERα and ERβ (2.2% and 2.8%, respectively). At this point we wanted to 
investigate the effect of the introduction of small alkyl groups on the aniline-type nitrogen atom. 
The N-methyl analogue showed a further improvement, especially on ERβ, in the binding 
affinities (RBA = 3.7% with ERα and 5.2% with ERβ). Surprisingly, the binding affinities of the 
immediately higher N-ethylated homologue were much lower than the N-Me derivative; in fact 
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its binding affinity on ERα dropped by about 10 fold and more than 100 fold on ERβ, compared 
to the N-Me analogue. 
 
 
 
Figure 4 
 
In order to understand the possible binding modes of these compounds and to explain the 
drop in binding affinity of the N-Et-anthranylaldoxime, we performed molecular docking 
experiments on ERα (Figure 5). 
In these experiments we found that the pseudo-ring A’ of N-H and N-Me-anthranylaldoxime 
could be positioned where estradiol had its phenolic A-ring, allowing for an efficient 
participation of the oxime OH in the same hydrogen-bonding network with Arg394 and Glu353 
in which estradiol is involved. The aromatic central cores of these compounds (indicated as B) 
perfectly replaces the B-ring of estradiol, and the two phenyl substituents protrude towards the 
relatively hydrophobic empty spaces in the receptor ligand binding pocket. 
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It should be noticed that N-Me-anthranylaldoxime places its N-methyl group in a small 
hydrophobic pocket defined by Leu346, Leu349, and Ala350 (Figure 5, left panel). 
Salicylaldoxime (not shown) displayed a similar spatial arrangement within the ERα binding 
domain. 
By contrast, the higher homologue with the N-ethyl substituent was not able to assume a 
similar binding mode within the ligand binding pocket as defined in the ERα-estradiol X-ray 
structure, when the pocket was rigidly fixed during the modeling. In fact, there is a steric clash 
between the N-Et substituent and the residue Leu349 (Figure 5, right panel). These repulsive van 
der Waals interactions that take place in the binding process of N-Et-anthranylaldoxime with the 
receptor might explain the much lower binding affinity values found for this compound. 
 
 
 
Figure 5 
 
A further examination of different classes of reported synthetic ER ligands shows that the 
introduction in these molecules of additional peripheral phenolic hydroxy-groups causes an 
improvement of their binding properties. This fact was explained by the intervention of 
additional hydrogen-bonds or other types of hydrophilic interactions between these new phenolic 
groups and other polar functions on residues present nearby in the ligand binding pocket of the 
receptor. 
Based on these considerations, we initially started to design and synthesize salicylaldoximes 
possessing polar groups in either one of the 3- and 4-aryl substituents, or in both of them. The 
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most promising compounds, in terms of binding affinity properties, turned out to be the ones 
having a single p-hydroxy group on the distal (4-position) or proximal (3-position) phenyl 
substituents (Figure 6). 
 
 
 
Figure 6 
 
An analysis of the results shows that the compound containing a p-hydroxy group only on the 
C(4) phenyl substituent (distal), possesses a binding affinity (2.6%, Figure 6) on ERα that is 2.5 
times better than its non-substituted counterpart (1.1%, Figure 4). This trend is accompanied by a 
slight decrease on ERβ (1.4% vs. 1.7%). On the other hand, the introduction of a p-hydroxy 
group on the C(3) phenyl substituent (proximal), caused a shift in the α/β preference in favor of 
the β subtype (β/α ≈ 2), due to a slight improvement of the affinity on ERβ (2.2%) with respect 
to its unsubstituted counterpart (1.7%). The compound possessing p-hydroxy groups in both 
phenyl substituents exhibited a decreased binding affinity on both ER subtypes with respect to its 
unsubstituted precursor, with a more striking reduction on ERβ. 
These results show that there are improvements in the RBA due to the introduction of only 
one hydroxyl substituent, with a certain preference for ERα when the p-OH group is placed on 
the distal phenyl, or for ERβ when the same group is placed on the proximal phenyl. However, 
when p-hydroxy groups are introduced in both phenyl substituents, the binding affinity values for 
both receptor subtypes were decreased. This might be due to the fact that ERs, especially ERβ, 
do not tolerate high levels of polarity. 
Evaluations on the effects of peripheral substituents in anthranylaldoximes are currently 
under investigation. 
As for the synthesis of these derivatives, an interesting synthetic strategy was developed for 
the preparation of hetero-disubstituted salicylaldoximes. The synthetic route included a double 
Pd-catalyzed cross-coupling reaction on a bromo-chloro-disubstituted aryl precursor (Scheme 1). 
This approach exploits the different reactivity of aryl-bromides and aryl-chlorides towards the 
chosen boronic acids under different reaction conditions, Suzuki-type conditions for the 
bromides22 and Fu-type conditions for the chlorides,23 and it provides an efficient way to 
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selectively introduce different substituents (depending on the boronic acid used) in those 
positions. 
 
 
 
Scheme 1 
 
As an example, the complete synthesis of salicylaldoxime containing a p-hydroxy group on 
the distal phenyl substituent is shown in Scheme 2. 2-Bromo-3-chloronitrobenzene24 was first 
submitted to a classical Suzuki-type cross-coupling reaction,22 using Pd(Ph3P)4 as the catalyst, to 
introduce the first phenyl group in the place of the bromine atom. This step did not affect the 
chlorine atom, which was then substituted in the second cross-coupling reaction with p-
methoxyphenyl boronic acid, using the more reactive catalytic system comprised of Pd2(dba)3 
together with tricyclohexylphosphine as the catalyst ligand.23 Under these conditions, it was 
possible to introduce the second aryl substituent in place of the aryl-chloride group efficiently, 
assembling the required diaryl-benzene core unit of these systems. 
The nitro-group was then reduced with hydrazine hydrate in the presence of catalytic 
amounts of ferric chloride and activated carbon. Diazotization of the amine function, followed by 
acid hydrolysis of the diazonium group, afforded the corresponding phenolic derivative. 
Treatment with allyl bromide gave the allyl ether, which was directly submitted to a Claisen 
rearrangement at 180 °C in N-methylaniline, affording the corresponding o-allyl-substituted 
phenol. The allylic terminal double bond was submitted to an alkaline isomerization to give E/Z 
diastereoisomeric mixtures of the compound possessing an internal aryl-conjugated double bond. 
The salicylaldehyde derivative was then obtained by oxidative cleavage of the double bond, 
using sodium periodate in the presence of catalytic amounts of osmium tetroxide. 
Transformation of the methoxy group into a hydroxyl was achieved by a BBr3 demethylation, 
and this hydroxyaryl-substituted salicylaldehyde, thus obtained, was then condensed with 
hydroxylamine hydrochloride in refluxing ethanol to give the final oxime. A similar synthetic 
scheme was followed for the preparation of the salicylaldoxime containing a p-hydroxy group on 
the proximal phenyl substituent, the only difference being in the inversion of the order of 
reaction of the two arylboronic acids. 
The (E)-geometry of the oxime moieties in all the compounds synthesized was assigned 
based on the chemical shift value of their oxime proton, which is in the δ 8.28-8.45 range. This 
value is typical for aromatic (E)-oximes, whereas the (Z)-oximes of the same kind usually have 
values in the δ 7.3-7.6 range. The downfield chemical shift found with oximes possessing the 
(E)-configuration is due to the greater shielding of the oxime proton when it is on the same side 
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and in a close spatial contact with an electronegative oxygen.25 The exclusive formation of 
oxime diastereoisomers of the (E)-configuration may be attributed to the stabilization of these 
diastereoisomers by the intramolecular hydrogen bond between the phenolic OH and the adjacent 
oxime nitrogen atom. 
 
 
 
Scheme 2 
 
The most active compounds were also assayed for transcriptional activity through both 
receptor subtypes. These cotransfection assays were conducted in human endometrial (HEC-1) 
cells, using expression plasmids for either full-length human ERα or ERβ and an estrogen-
responsive luciferase reporter gene system.26
A representative example of complete dose-response curves is given by N-H 
anthranylaldoxime shown in Figure 7. In these plots, transcriptional activity (full curve) is 
normalized relative to that obtained with 1 nM estradiol, which is set at 100% and antagonist 
activity (dashed curve) was assayed in the presence of 1nM estradiol. 
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Figure 7 
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The full dose-response curves show that N-H anthranylaldoxime is a partial agonist on ERα 
and a partial antagonist on ERβ. The other anthranylaldoxime and salicylaldoxime derivatives 
show similar transcriptional efficacies, always characterized by a greater level of agonism on 
ERα than on ERβ. 
 
 
Conclusions 
 
This study was carried out with the aim of finding new SERMs with better biopharmacological 
profiles. The results obtained with these two classes of salicylaldoximes and anthranylaldoximes 
show that these compounds are able to efficiently bind both ERα and ERβ. Moreover, the 
transcriptional activity assays revealed that these compounds possess good modulatory properties 
on both receptor subtypes and, therefore, may be potentially developed as future efficient 
SERMs. 
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